Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

REFERENCES

• Parl F. F., Schmidt B. P., Dupont W. D., Wagner R. K. Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 1984; 54: 2237–2242
   PubMed Web of Science ®Google Scholar
• Pichon M. F., Broet P., Magdelenat H., et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996; 73: 1545–1551
   PubMed Web of Science ®Google Scholar
• Sorlie T., Perou C. M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869–10874
   PubMed Web of Science ®Google Scholar
• Nielsen T. O., Hsu F. D., Jensen K., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367–5374
   PubMed Web of Science ®Google Scholar
• Soutirou C., Neo S. Y., McShane L. M., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393–10398
   PubMed Web of Science ®Google Scholar
• Kim M. J., Ro J. Y. R., Ahn S. H., et al. Clinicopathlogic significance of the basal-like subtype of breast cancer: a comparison with hormone-receptor and Her-2/neu-overexpressing phenotypes. Hum Pathol 2006; 37: 1217–1226
   PubMed Web of Science ®Google Scholar
• Hafty B. G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652–5657
   PubMed Web of Science ®Google Scholar
• Cleator S., Heller W., Coombes R C. Triple-negative breast cancer: therapeutic options. Lancet 2007; 8: 235–244
   PubMed Web of Science ®Google Scholar
• Trendall-Smith N. J., Peston D., Shousha S. Adenoid cycstic carcinoma of the breast:a tumor commonly devoid of oestrogen receptors and related proteins. Histopathology 1999; 35: 241–248
   PubMed Web of Science ®Google Scholar
• Rosen P. P., Cranor M L. Secretory carcinoma of the breast. Arch Pathol Lab Med 1991; 115: 141–144
   PubMed Web of Science ®Google Scholar
• Santen R. J., Song R. X., McPherson R., et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Ster Biochem Mol Biol 2002; 80: 239–256
   PubMed Web of Science ®Google Scholar
• Small G. W., Shi Y. Y., Higgins L. S., Orlowski R Z. Mitogen-activated protein (MAP) kinase Phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res 2007; 67: 4459–4466
   PubMed Web of Science ®Google Scholar
• Denhardt D T. Signal transduction protein phosphorilation cascades mediated by Ras/Rho proteins in the mammalian cell: The potential for multiplex signalling. Biochem J 1996; 318: 729–747
   PubMed Web of Science ®Google Scholar
• Neve R. M., Holbro T., Hynes N E. Distinct roles for phosphoinositide 3-kinase, mtogen-activated protein-kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene 2002; 21: 4567–4576
   PubMed Web of Science ®Google Scholar
• Eralp Y., Derin D., Ozluk Y., et al. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 2007, doi: 10.1093/annonc/mdm522
   PubMed Web of Science ®Google Scholar
• Rakha E. A., El-Sayed M. E., Green A. R., et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25–32
   PubMed Web of Science ®Google Scholar
• Gullick W. J., Love S. B., Wright C., et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434–438
   PubMed Web of Science ®Google Scholar
• Paik S., Hazan R., Fisher E. R., et al. Pathologic findings from the National Surgical Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103–112
   PubMed Web of Science ®Google Scholar
• Press M. F., Bernstein L., Thomas P. A., et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15(8)2894–2904
   PubMed Web of Science ®Google Scholar
• Riou G., Mathieu M. C., Barrois M., et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001; 95(4)266–270
   PubMed Web of Science ®Google Scholar
• Ross J. S., Fletcher J A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998; 16(6)413–428
   PubMed Web of Science ®Google Scholar
• Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403–410
   Google Scholar
• Henson D. E., Ries L., Freedman L. S., Carriaga M. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991; 68: 2142–2149
   PubMed Web of Science ®Google Scholar
• Schumacher M., Schmoor C., Sauerbrei W., et al. The prognostic value for histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993; 25: 235–245
   PubMed Web of Science ®Google Scholar
• Reed W., Hannisdal E., Boehler P. J., et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow up of 14 to 30 years. Cancer 2000; 88: 804–813
   PubMed Web of Science ®Google Scholar
• Jeng M. H., Shupnik M. A., Bender T. P., et al. Estrogen receptor expression and function in kong-term estrogen deprived human breast cancer cells. Endocrinology 1998; 139: 4164–4174
   PubMed Web of Science ®Google Scholar
• Shim W. S., Conaway M., Masamura S., et al. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen-deprived human breast cancer cells in vivo. Endocrinology 2000; 141: 396–405
   PubMed Web of Science ®Google Scholar
• Salh B., Marotta C., Mattewson C., et al. Investigation of the MEK-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res 1999; 19: 731–740
   PubMed Web of Science ®Google Scholar
• Moyano J. V., Evans J. R., Chen F., et al. Alpha-B-crytallin is a novel onco-protein that predicts poor clinical outcome in breast cancer. J Clin Invest 2006; 116: 261–270
   PubMed Web of Science ®Google Scholar
• Esteva F. J., Hortobagyi G. N., Sahin A. A., et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using immunohistochemistry. Pathol Oncol Res 2001; 7: 171–177
   PubMedGoogle Scholar
• Esteva F. J., Sahin A. A., Smith T. L., et al. Prognostic significance of phosphorilated P38 mitogen-activated protein kinase and Her-2 expression in lymph node-positive breast carcinoma. Cancer 2004; 100: 499–506
   PubMed Web of Science ®Google Scholar
• Oh A. S., Lorant L. A., Holloway J. N., et al. Hyperactivation of MAPK induces loss of Eralpha expression in breast cancer cells. Molec Endocrinol 2001; 15: 1344–1359
   PubMed Web of Science ®Google Scholar
• Lu C., Speers C., Zhang Y., et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen-receptor-negative mammary tumors. J Natl Cancer Inst 2003; 95: 1825–1833
   PubMed Web of Science ®Google Scholar
• Creighton C. J., Hilger A. M., Murthy S., et al. Activation of mitogen-activated protein (MAP) kinase in estrogen recetor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor negative human breast tumors. Cancer Res 2006; 66: 3903–3911
   PubMed Web of Science ®Google Scholar
• Gutierrez C. M., Detre S., Johnston S., et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, Her-2, and p38 mitogen activated protein kinase. J Clin Oncol 2005; 23: 2469–2476
   PubMed Web of Science ®Google Scholar
• Gee J. M. W., Robertson J. F. R., Ellis I. O., Nicholson R I. Phosphorilation of ERK1/2 mitogen-activated protein (MAP) kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247–254
   PubMed Web of Science ®Google Scholar
• Mueller H., Flury N., Eppenberger-Castori S., et al. Potential prognostic value of mitogen-activated protein (MAP) kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 2000; 89: 384–388
   PubMed Web of Science ®Google Scholar
• von Lintig F. C., Dreilinger A. D., Varki N. M., et al. Ras activation in human breast cancer. Breast Can Res Treat 2000; 62: 51–62
   PubMed Web of Science ®Google Scholar
• McCubrey J. A., Steelman L. S., Abrams S. L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul 2006; 46: 249–279
   PubMedGoogle Scholar
• Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., et al. Suppression of c-Myc induced apoptosis by Ras signalling through PI3K and PKB. Nature 1997; 385: 544–548
   PubMed Web of Science ®Google Scholar
• Pearson G., Robinson F., Beers G. T., et al. Mitogen-activated protein-kinase pathways:regulation and physiological functions. Endocrine Rev 2001; 22: 153–183
   PubMed Web of Science ®Google Scholar
• Davis H., Bignell G. R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–954
   PubMed Web of Science ®Google Scholar